‘Unlawful Marketing’ Doesn't Establish Dietary Ingredients' Use Before Drug Approval Or Study
Executive Summary
FDA explains thinking in a letter to Inner Mongolia Kingdomway Pharmaceutical after rejecting Chinese firm’s NDI notification for N-acetyl-L-cystein. Prior to its investigation as a drug, NMN wasn’t used in supplements available in US, “except unlawfully without an NDI notification.”
You may also be interested in...
‘Recipe For Disaster’ In Supplement Manufacturing? US DoJ Attorney Cooks Up Likely Causes
"You end up with a recipe for maybe there's adulterants in the product. Maybe the product wasn't manufactured according to the spec, so it's misbranded. Worse, there could be adulterants. In some of those ingredients, there's a lot of potential failures,” says Patrick Runkle, senior litigation counsel at DoJ Consumer Protection Branch, during FDL conference.
US FDA Supplement Facility Inspection Numbers Back To Typical Along With GMP Problems Found
Supplement facility GMP inspections by FDA in 2022 along with the frequency of form 483s sent to firms following inspections return to roughly pre-pandemic annual numbers after dipping during 2020 and 2021.
US OTC Monograph Drug Facility Fees Up 8%, Higher Price Tags Stuck On OMORs, Too
FY2023 OTC monograph user fee target facility fee revenue is $25.4m from manufacturers’ fees of $26,153 and contract manufacturers’ fees of $17,435, all due by 1 June. OMOR fees are $517,381 for Tier 1 requests and $103,476 for Tier 2.